Completed PHASE1 INTERVENTIONAL 3-arm NCT04218513

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

An Experiment to Evaluate the Drug-drug Interaction of Formula Edaravone and Formula 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

Sponsor: Nanjing Yoko Biomedical Co., Ltd.

Conditions Drug-drug Interaction

Interventions 2-Aminoethanesulfonic Acid Injection Compound Edaravone Injection Edaravone Injection

Updated 5 times since 2020 Last updated: Mar 19, 2021 Started: May 10, 2019 Primary completion: May 31, 2019 Completion: May 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug-drug Interaction and is currently completed. Nanjing Yoko Biomedical Co., Ltd. leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE1
Feb 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing Yoko Biomedical Co., Ltd.

Data source: Nanjing Yoko Biomedical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China